Estrogen Receptor Positive (ER+) Breast Cancer - cost of treatment, development partner, patent expiry date, sales data etc. (1)

1
Estrogen Receptor Positive (ER) Breast Cancer -
Treatment Landscape Competitive Analysis, 2016
Published on - 04 July, 2016 Number of pages
90 Single User Price 2450
MarketIntelReports, Estrogen Receptor Positive
(ER) Breast Cancer - Treatment Landscape
Competitive Analysis, 2016, report provides
comprehensive insights about the treatment
landscape across this indication. This report
also provides the deep understanding of the
stages of the Estrogen Receptor Positive (ER)
Breast Cancer, epidemiology, risk factors,
diagnosis etc.
Click Here To Check Complete Report
2
A key objective of the report is to establish the
understanding of the treatment landscape and
competitive analysis of the Estrogen Receptor
Positive (ER) Breast Cancer which mainly
describes the treatment of breast cancer at
different stages. Breast cancer is the condition
where the cells of the breast area become
tumorous, that is, they undergo unlimited cell
division. Both women and men are affected but
chances of men being diagnosed with breast cancer
are rare. Each year about 2,300 new cases of
breast cancer in men and about 230,000 new cases
in women are diagnosed. It is the second most
common cancer among women in USA.
Avail more information from Sample Brochure of
report
3
This report provides the insights of the marketed
drugs for the Estrogen Receptor Positive (ER)
Breast Cancer which includes the Targeted
Therapy, Hormone Therapy and Chemotherapy. In
case of Estrogen Receptor Positive (ER) Breast
Cancer, Hormone therapy is the main focus of
treatment after surgery and chemotherapy.
Hormonal therapy is usually recommended after 5
years of surgery and can be divided into Estrogen
blocking hormonal therapy and estrogen lowering
hormonal therapy based on the mechanism of action
of the hormonal therapy drugs. Of all the
late-stage pipeline drugs, Buparlisib is expected
to reach the market in the next few
years. Recent report of MarketIntelReports
covers the treatment landscape which provides the
treatment options by different stages and type of
the breast cancer. There are four chemotherapy
drugs, six hormone therapy drugs and one targeted
therapy drugs in market for the treatment of
Estrogen Receptor Positive (ER) Breast Cancer.
Note This report will be delivered to the
client in 48 hours
4

• Report Highlights
• The new report, provides a Estrogen Receptor
  Positive (ER) Breast Cancer Treatment Landscape
  across the globe
• The report provides profiles of the marketed drug
  which includes the product description, cost of
  treatment, development partner, patent expiry
  date, sales data etc.
• Comparative analysis of marketed drugs by
  therapy, cost of treatment, Therapeutic Class.
  Coverage of the Estrogen Receptor Positive (ER)
  Breast Cancer Phase III and Pre-registration
  Drugs Analysis by product type, molecule type,
  route of administration, Median Progression Free
  Survival
• The report reviews key players involved in the
  therapeutics development for Estrogen Receptor
  Positive (ER) Breast Cancer and also provide
  market barriers, market drivers and opportunities
• Provides Phase III products assessment by line of
  therapy and target.

Make an Inquiry Before Buying
5
Estrogen Receptor Positive (ER) Breast Cancer -
Treatment Landscape Competitive Analysis, 2016
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
Estrogen Receptor Positive (ER) Breast Cancer -
Treatment Landscape Competitive Analysis, 2016
and future opportunities are provided in the
report.
Contact 1-302-261-5343 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Estrogen Receptor
Positive (ER) Breast Cancer Market Report